- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Examining to aid CureVac with experimental COVID-19 vaccine: Bayer CEO
Berlin: German pharmaceutical giant Bayer is examining whether it can help CureVac to produce its experimental COVID-19 vaccine, its chief executive was quoted as saying on Sunday.
Though inoculation campaigns have started around the world using various COVID-19 vaccines, many countries say their ability to get shots into arms is being limited by lower than expected supplies owing to a shortage of production.
"We are prepared to pull out all the stops for this," Werner Baumann told the Welt am Sonntag newspaper.
"This is not primarily about financial considerations but about making the vaccine available as quickly as possible."
Bayer agreed this month to help fellow German company CureVac with development of its COVID-19 vaccine candidate, which is in late-stage clinical trials and has not yet been approved.
Baumann said the drugmaker was "intensively examining" whether to expand its co-operation to include manufacturing the vaccine for CureVac.
Read also: Bayer, Arogya Finance collaborate to introduce Eylea Easy Pay Program in India
"With our production network in Germany and the USA and the corresponding lead time, we would in principle be in a position to produce vaccine in larger quantities," he said.
On Friday U.S. drugmaker Pfizer said there would be a temporary slowdown of shipments of the vaccine it developed with German partner BioNTech, citing changes in manufacturing processes to boost output.
Read also: Bayer gets USFDA Priority Review for finerenone for type 2 diabetes, CKD
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751